- Nivolumab-cabozantinib doublet is effective as first-line treatment in advanced RCC
Choueiri TK, et al. ESMO 2020 Virtual Meeting, abstract 696O. - Trials with chemoimmunotherapy in metastatic TNBC show contradicting results
Emens LA, et al. ESMO 2020 Virtual Meeting, abstract LBA16; Miles DW, et al. ESMO 2020 Virtual Meeting, abstract LBA15. - Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence
Tsuboi M, et al. ESMO 2020 Virtual Meeting, abstract LBA1. - CDK4/6 inhibitor palbociclib effective in ER+ advanced endometrial cancer
Mirza MR, et al. ESMO 2020 Virtual Meeting, abstract LBA28. - Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?
Möhler M, et al. ESMO 2020 Virtual Meeting, abstract LBA6; Boku N, et al. ESMO 2020 Virtual Meeting, abstract LBA7. - Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC
Solomon B, et al. ESMO 2020 Virtual Meeting, abstract LBA2.
Posted on
Previous Article
« Non-physicians may optimize heart failure drugs remotely Next Article
Bicuspid-aortic-valve repair shows long-term efficacy »
« Non-physicians may optimize heart failure drugs remotely Next Article
Bicuspid-aortic-valve repair shows long-term efficacy »
Table of Contents: ESMO 2020
Featured articles
COVID-19 and Cancer
Breast Cancer
Gastrointestinal Cancers
Lung Cancer
Melanoma
Genitourinary Cancers
Bladder cancer risk and early detection
Gynaecological Cancers
Basic Science
Related Articles
November 25, 2020
Consolidation ipilimumab and nivolumab in limited stage SCLC

September 23, 2020
ESMO 2020 Highlights Podcast
November 25, 2020
Immuno-combination therapy in metastatic melanoma
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy